Document text
Principal Investigator: Yan Tang
Organization: TUFTS UNIVERSITY MEDFORD
Fiscal Year: 2024
Award: $659,481
Funding agency: National Heart Lung and Blood Institute
Abstract
Lymphangioleiomyomatosis (LAM) is a genetic disorder caused by bi-allelic inactivating mutations in tumor
suppressor genes TSC1 or TSC2, leading to progressive lung destruction and eventually the requirement for
lung transplantation. Rapalogs, the only FDA-approved treatments for LAM, induce a cytostatic effect with
stabilized lung function. However, lung function continues to decline upon treatment cessation. Thus, there is
an urgent need for better treatment, potentially leading to a cure for this devastating disease.
The monogenetic nature of LAM makes messenger RNA (mRNA) replacement an attractive therapeutic
modality, which requires safe and efficacious delivery of functional mRNA to the lung and specifically into TSC-
deficient cells. We have developed lung-specific synthetic lipid nanoparticles (LNPs) and showed in our
preliminary data that in vivo organ-selectivity of LNPs can be precisely tuned by changing the linker structure in
the lipidoid tails without complicating the LNPs formulation. Furthermore, we developed LAM cell-targeting hybrid
LNPs that efficiently deliver functional TSC2 mRNA into TSC2-deficient cells and suppress mTORC1 pathway.
mRNA replacement therapy significantly reduced tumor burdens in preclinical LAM models. Remarkably, mRNA
therapy induced T cell tumor infiltration in the otherwise immune cold tumor microenvironment.
We hypothesize: 1) improved lung-specific tumor-targeting LNPs will assist developing mRNA therapy for LAM,
which provides a novel therapeutic strategy to achieve durable effects and complete response; 2) LNP-assisted
mRNA therapy can reprogram LAM-like cells back to a “normal” state without affecting normal tissue, and can
re-normalize LAM microenvironment; 3) multi-omic single cell analysis will reveal mechanism of action of mRNA
therapy and help improve LNP design. Our hypotheses will be tested in the following Aims:
Aim 1. To develop and optimize lung-specific synthetic lipid nanoparticles for LAM-targeted mRNA therapy.
Aim 2. To determine therapeutic efficacy of LAM-targeting nanoparticle-assisted mRNA therapy for LAM.
Aim 3. To determine mRNA therapy-induced LAM cell reprogramming and LAM microenvironment remodeling
by integrative single cell multiomic analyses.
The scientific and preclinical impact of this project are 1) development of LAM cell-targeted mRNA therapy;
2) proof-of-concept that mRNA therapy can achieve durable response; 3) molecular understanding of LAM cell
reprogramming and LAM microenvironment restoration by mRNA therapy. The success of this study will open
a new therapeutic paradigm of mRNA therapy with the potential of durable effects and complete remissions.
Terms: <2019-nCoV vaccine><Acrylamides><Adverse effects><Affect><Alleles><Allelomorphs><Amides><Amines><Anti-Oncogenes><Antioncogenes><Back><Bourneville Disease><Bourneville Phakomatosis><Bourneville syndrome><Bourneville-Brissaud disease><Bourneville-Pringle syndrome><COVID-19 vaccine><Cancer Suppressor Genes><Categories><Cell Body><Cell Reprogramming><Cells><Combination immunotherapy><Control Groups><Cytostatic Agents><Cytostatic Drugs><Cytostatics><Data><Development><Disease><Disease remission><Disorder><Dorsum><Emerogenes><Engineering><Epiloia><FDA approved><Formulation><Genes><Genetic Alteration><Genetic Change><Genetic Diseases><Genetic defect><Hybrids><Hyperactivity><Immune><Immunes><In complete remission><Lesion><Lung><Lung Diseases><Lung Grafting><Lung Lymphangioleiomyomatosis><Lung Respiratory System><Lung Transplantation><Lymphangioleiomyomatosis><Lymphangiomyomatosis><Medicine><Messenger RNA><Mice><Mice Mammals><Modality><Modeling><Modification><Molecular><Molecular Mechanisms of Action><Murine><Mus><Mutation><Nature><Nodule><Non-Polyadenylated RNA><Normal Tissue><Normal tissue morphology><Onco-Suppressor Genes><Oncogenes-Tumor Suppressors><Organ><Pathway interactions><Patients><Pringle disease><Production><Protein Replacement Therapy><Proteins><Proteomics><Pulmonary Diseases><Pulmonary Disorder><Pulmonary Graft><Pulmonary Transplant><Pulmonary Transplantation><RNA><RNA Gene Products><RNA based therapeutics><RNA based therapy><RNA replacement><RNA therapy><Rapamune><Rapamycin><Reaction><Recessive Oncogenes><Remission><Replacement Therapy><Ribonucleic Acid><SARS-CoV-2 vaccine><SARS-coronavirus-2 vaccine><Series><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe acute respiratory syndrome coronavirus 2 vaccine><Sirolimus><Specificity><Structure><System><T cell infiltration><T-Cells><T-Lymphocyte><TSC2><TSC2 gene><TSC4><TSC4 Gene><Tail><Testing><Therapeutic><Time><Treatment Efficacy><Tuberin><Tuberous Sclerosis><Tumor Burden><Tumor Load><Tumor Suppressing Genes><Tumor Suppressor Genes><Withholding Treatment><adenoma sebaceum><amine><cancer infiltrating T cells><cancer microenvironment><cellular reprogramming><cerebral sclerosis><cessation of treatment><circular RNA><clinical translation><clinically translatable><closed circular RNA><combinatorial immunotherapy><complete response><coronavirus disease 2019 vaccine><coronavirus disease-19 vaccine><deliver mRNA><deliver messenger RNA><delivery system for mRNA><design><designing><developmental><disease model><disease of the lung><disorder model><disorder of the lung><dual immunotherapy><enzyme replacement therapy><epiploia><genetic condition><genetic disorder><genome mutation><global gene expression><global transcription profile><hereditary multiple system hamartomatosis><immune microenvironment><immunosuppressive microenvironment><immunosuppressive tumor microenvironment><improved><in vivo><inhibitor><intervention efficacy><lipid based nanoparticle><lipid nanoparticle><lipidomics><lung disorder><lung function><lung transplant><mRNA><mRNA delivery><messenger RNA delivery><metabolism measurement><metabolome><metabolomics><metabonome><metabonomics><mouse model><multi-modality><multimodality><multiomics><multiple omics><murine model><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nano particle><nano particle delivery><nano-sized particle><nanocomplexes><nanoparticle><nanoparticle delivered><nanoparticle delivery><nanosized particle><neurinomatosis centralis><neuromatosis universalis><neurospongioblastosis diffusa><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation therapeutics><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><oncosuppressor gene><panomics><pathway><phacomatosis><pre-clinical><pre-clinical study><preclinical><preclinical study><programs><pulmonary><pulmonary function><pulmonary lymphangioleiomyomatosis><rare genetic disease><rare genetic disorder><response><restoration><sclerosis tuberosa><side effect><single cell analysis><spongioblastosis circumscripta><success><therapeutic RNA><therapeutic efficacy><therapy efficacy><thymus derived lymphocyte><transcriptome><transcriptomics><treatment cessation><tuberose sclerosis><tuberous sclerosis complex><tumor><tumor growth><tumor immune microenvironment><tumor infiltrating T cells><tumor microenvironment><tumor-immune system interactions><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidates against SARS-CoV-2><vaccine for novel coronavirus><vaccines preventing COVID><vaccines to prevent COVID>